Evidence map›Paper›PMID 38953367›Full record

SynthesisClinical cardiology2024

Assessment of Myocardial Viability in Ischemic Cardiomyopathy With Reduced Left Ventricular Function Undergoing Coronary Artery Bypass Grafting.

Arian Arjomandi Rad, Eleni Tserioti, Dimitrios E Magouliotis, Robert Vardanyan, Ilias V Samiotis, John Skoularigis, Ben Ariff, Andrew Xanthopoulos, Filippos Triposkiadis, Roberto Casula and 1 more

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Clinical cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Arian Arjomandi RadDivision of Medical Sciences, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0002-4931-4049
Eleni TseriotiDepartment of Surgery and Cancer, Imperial College London, London, UK.
Dimitrios E MagouliotisDepartment of Cardiothoracic Surgery, University Hospital of Larissa, Larissa, Greece.
Robert VardanyanDepartment of Surgery and Cancer, Imperial College London, London, UK.
Ilias V SamiotisDepartment of Cardiothoracic Surgery, University Hospital of Larissa, Larissa, Greece.
John SkoularigisDepartment of Cardiology, University Hospital of Larissa, Larissa, Greece.
Ben AriffDepartment of Radiology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
Andrew XanthopoulosDepartment of Cardiology, University Hospital of Larissa, Larissa, Greece.
Filippos TriposkiadisDepartment of Cardiology, University Hospital of Larissa, Larissa, Greece.
Roberto CasulaDepartment of Surgery and Cancer, Imperial College London, London, UK.
Thanos AthanasiouDepartment of Surgery and Cancer, Imperial College London, London, UK.

Funding

The authors received no specific funding for this work.
6 · The paper itself

Abstract

backgroundWe aim to provide a comprehensive review of the current state of knowledge of myocardial viability assessment in patients undergoing coronary artery bypass grafting (CABG), with a focus on the clinical markers of viability for each imaging modality. We also compare mortality between patients with viable myocardium and those without viability who undergo CABG.

methodsA systematic database search with meta-analysis was conducted of comparative original articles (both observations and randomized controlled studies) of patients undergoing CABG with either viable or nonviable myocardium, in EMBASE, MEDLINE, Cochrane database, and Google Scholar, from inception to 2022. Imaging modalities included were dobutamine stress echocardiography (DSE), cardiac magnetic resonance (CMR), single-photon emission computed tomography (SPECT), and positron emission tomography (PET).

resultsA total of 17 studies incorporating a total of 2317 patients were included. Across all imaging modalities, the relative risk of death post-CABG was reduced in patients with versus without viability (random-effects model: odds ratio: 0.42; 95% confidence interval: 0.29-0.61; p < 0.001). Imaging for myocardial viability has significant clinical implications as it can affect the accuracy of the diagnosis, guide treatment decisions, and predict patient outcomes. Generally, based on local availability and expertise, either SPECT or DSE should be considered as the first step in evaluating viability, while PET or CMR would provide further evaluation of transmurality, perfusion metabolism, and extent of scar tissue.

conclusionThe assessment of myocardial viability is an essential component of preoperative evaluation in patients with ischemic heart disease undergoing surgical revascularization. Careful patient selection and individualized assessment of viability remain paramount.

Indexed as

Coronary Artery BypassMyocardial IschemiaVentricular Function, LeftCardiomyopathiesCoronary Artery DiseaseEchocardiography, StressHumansMyocardiumTissue SurvivalTomography, Emission-Computed, Single-PhotonVentricular Dysfunction, LeftCABGheart failuremyocardial viability

Identifiers

PMID38953367
PMCPMC11217808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.